Type 2 Diabetes Mellitus (T2DM)NRG4-T2DMNCT07734558
Evaluation of Neuregulin-4 (NRG4) Levels in Obese and Non-Obese Patients With Type 2 Diabetes Mellitus
An observational study of Type 2 Diabetes Mellitus (T2DM) and Obesity Type 2 Diabetes Mellitus, run by GÜLDEN ANATACA at 1 site in Turkey (Türkiye).
Trial summary
This prospective observational study aims to evaluate serum Neuregulin-4 (NRG4) concentrations in obese and non-obese adults with Type 2 Diabetes Mellitus (T2DM) and to investigate their association with obesity status, insulin resistance, and different antidiabetic treatment regimens. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus, Insulin Resistance
- How many people
- 125 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- Jun 2026to 30 Dec 2026
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population will consist of obese and non-obese adult participants aged 18-65 years who are admitted to the outpatient clinic. The study will include newly diagnosed treatment-naive Type 2 Diabetes Mellitus patients, patients with at least 6 months of Type 2 DM diagnosis receiving different antidiabetic treatment combinations, and healthy control participants without diabetes mellitus.
Who may be able to join
- Age 18-65 years
- Newly diagnosed treatment-naïve T2DM
- T2DM treated for at least 6 months
- BMI >30 kg/m²
- BMI <25 kg/m²
- No pregnancy
Show all 10Show fewer
- No breastfeeding
- No active infection
- No inflammatory disease
- Written informed consent
Who cannot join
- Age <18 years
- Pregnancy
- Breastfeeding
- Active infection
- Rheumatologic disease
- Refusal to participate
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Kanuni Sultan Süleyman Training and Research Hospital
Istanbul
gülden ANATACA, +905059284244, ganataca@yahoo.com
About this study
Official title: Evaluation of the Relationship Between Serum Neuregulin-4 (NRG4) Levels, Obesity Status, and Antidiabetic Treatment Regimens in Patients With Type 2 Diabetes Mellitus: A Prospective Observational Study
This prospective observational study aims to evaluate serum Neuregulin-4 (NRG4) concentrations in obese and non-obese adults with Type 2 Diabetes Mellitus (T2DM) and to investigate their association with obesity status, insulin resistance, and different antidiabetic treatment regimens. Participants will be categorized into five predefined groups according to obesity status and treatment regimen, including SGLT2 inhibitor users, non-SGLT2 oral antidiabetic therapy users, SGLT2 combination therapy users, newly diagnosed treatment-naïve patients, and healthy controls. Clinical, anthropometric, and laboratory parameters including fasting plasma glucose, HbA1c, estimated glomerular filtration rate (eGFR), body mass index, waist circumference, waist-to-hip ratio, and serum NRG4 concentrations will be evaluated. The study aims to determine whether NRG4 may serve as a novel biomarker reflecting metabolic status and treatment response in patients with T2DM.
Read the detailed description
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, resulting in persistent hyperglycemia and an increased risk of both microvascular and macrovascular complications. Obesity is one of the strongest risk factors for the development and progression of T2DM and is associated with chronic low-grade inflammation, dysregulated adipokine secretion, and impaired glucose and lipid metabolism. Despite advances in antidiabetic therapies, identifying novel biomarkers that reflect metabolic status and treatment response remains an important research priority.
Neuregulin-4 (NRG4) is a recently identified adipokine predominantly secreted by brown adipose tissue. Experimental and clinical studies have demonstrated that NRG4 plays an important role in maintaining metabolic homeostasis by regulating glucose metabolism, improving insulin sensitivity, suppressing hepatic lipogenesis, and reducing systemic inflammation. Reduced circulating NRG4 concentrations have been associated with obesity, insulin resistance, non-alcoholic fatty liver disease, metabolic syndrome, and Type 2 Diabetes Mellitus. Lower serum NRG4 levels may therefore represent a potential biomarker of metabolic dysfunction and disease severity.
Although previous studies have investigated the association between serum NRG4 concentrations and obesity or T2DM separately, limited evidence is available regarding the relationship between NRG4 levels, obesity status, and different antidiabetic treatment regimens within the same patient population. In particular, the potential influence of sodium-glucose cotransporter-2 (SGLT2) inhibitors and other commonly used antidiabetic therapies on circulating NRG4 concentrations has not been adequately investigated.
This single-center, prospective observational study aims to evaluate serum NRG4 concentrations in obese and non-obese adults with Type 2 Diabetes Mellitus and to investigate their relationship with different antidiabetic treatment regimens. Participants will be consecutively recruited from the outpatient clinic and classified into five predefined groups according to diabetes status and current treatment regimen: (1) patients receiving SGLT2 inhibitor monotherapy; (2) patients receiving oral antidiabetic therapy without SGLT2 inhibitors; (3) patients receiving combination therapy including SGLT2 inhibitors; (4) newly diagnosed treatment-naïve patients with T2DM; and (5) healthy individuals without diabetes who will serve as the control group.
Clinical and demographic characteristics including age, sex, body mass index (BMI), waist circumference, waist-to-hip ratio, smoking status, and current antidiabetic medications will be recorded. Routine biochemical parameters, including fasting plasma glucose, glycated hemoglobin (HbA1c), and estimated glomerular filtration rate (eGFR), will be obtained from routine clinical evaluations. In addition, one peripheral venous blood sample will be collected from each participant for serum NRG4 measurement. Blood samples will be centrifuged, serum aliquots will be stored at -80°C, and serum NRG4 concentrations will be measured using a validated enzyme-linked immunosorbent assay (ELISA).
The primary outcome of the study is the comparison of serum NRG4 concentrations among the predefined study groups. Secondary analyses will evaluate the associations between serum NRG4 concentrations and obesity-related anthropometric measurements, glycemic control, renal function, and different antidiabetic treatment modalities.
The findings of this study are expected to improve the understanding of the role of NRG4 in the pathophysiology of obesity and Type 2 Diabetes Mellitus and may provide evidence supporting the clinical utility of NRG4 as a novel biomarker for metabolic status and treatment response. The results may also contribute to the identification of future therapeutic targets for patients with obesity and T2DM.
- Keywords
- Neuregulin-4, NRG4, Type 2 Diabetes Mellitus, Obesity, Adipokine
- Medical subject headings
- Diabetes Mellitus, Type 2, Insulin Resistance, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| SGLT2 Group | Type 2 Diabetes Mellitus patients receiving only SGLT2 inhibitor treatment will be included in this group. Serum NRG4 levels and metabolic parameters will be evaluated. | |
| Non-SGLT2 OAD Group | Type 2 Diabetes Mellitus patients receiving metformin with or without insulin therapy, but not receiving SGLT2 inhibitors, will be included in this group. | |
| SGLT2 Combination Group | Type 2 Diabetes Mellitus patients receiving metformin with or without insulin together with SGLT2 inhibitor therapy will be included in this group. | |
| Newly Diagnosed DM Group | Newly diagnosed treatment-naive Type 2 Diabetes Mellitus patients who have not received any antidiabetic therapy will be included in this group. | |
| Healthy Control Group | Age-matched participants without Diabetes Mellitus diagnosis will be included as healthy controls for comparison of serum NRG4 levels and metabolic parameters. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum Neuregulin-4 (NRG4) Levels in Obese and Non-Obese Type 2 Diabetic Patients
The primary outcome of this study is the evaluation and comparison of serum Neuregulin-4 (NRG4) levels among obese and non-obese patients with Type 2 Diabetes Mellitus receiving different antidiabetic treatment modalities, as well as healthy control subjects.
Measured: Baseline (Day 0)
Secondary outcomes (4)
Glycated Hemoglobin (HbA1c)
HbA1c (%) will be measured to evaluate long-term glycemic control and compared among all study groups.
Measured: Baseline (Day 0)
Fasting Plasma Glucose
Fasting plasma glucose (mg/dL) will be measured and compared among the study groups.
Measured: Baseline (Day 0)
Estimated Glomerular Filtration Rate (eGFR)
Estimated glomerular filtration rate (mL/min/1.73 m²) will be evaluated to assess renal function and compared among the study groups.
Measured: Baseline (Day 0)
Body Mass Index (BMI)
Body mass index (kg/m²) will be calculated using body weight and height and compared between obese and non-obese participants.
Measured: Baseline (Day 0)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2026
- Study startJun 2026 (estimated)
- Primary completion30 Aug 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Type 2 Diabetes Mellitus (T2DM)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 125 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- GÜLDEN ANATACA
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, GÜLDEN ANATACA, Istanbul Saglik Bilimleri University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07734558
- Sponsor's protocol ID
- KAEK/2026.04.1 l8
- Acronym
- NRG4-T2DM
- Status last verified
- Jul 2026
- First submitted
- 16 Jul 2026
- Last updated
- 29 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: ndividual participant data (IPD) will not be shared in order to protect participant confidentiality and privacy. The study will report only aggregated and anonymized data in scientific publications and presentations.
Publications
Tutunchi H, Mobasseri M, Aghamohammadzadeh N, Hooshyar J, Naeini F, Najafipour F. Serum neuregulin 4 (NRG-4) level and non-alcoholic fatty liver disease (NAFLD): A case-control study. Int J Clin Pract. 2021 Oct;75(10):e14555. doi: 10.1111/ijcp.14555. Epub 2021 Jun 29.
PubMed 34159710Cai C, Lin M, Xu Y, Li X, Yang S, Zhang H. Association of circulating neuregulin 4 with metabolic syndrome in obese adults: a cross-sectional study. BMC Med. 2016 Oct 24;14(1):165. doi: 10.1186/s12916-016-0703-6.
PubMed 27772531Wang GX, Zhao XY, Meng ZX, Kern M, Dietrich A, Chen Z, Cozacov Z, Zhou D, Okunade AL, Su X, Li S, Bluher M, Lin JD. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. Nat Med. 2014 Dec;20(12):1436-1443. doi: 10.1038/nm.3713. Epub 2014 Nov 17.
PubMed 25401691Yan P, Xu Y, Wan Q, Feng J, Li H, Yang J, Zhong H, Zhang Z. Plasma Neuregulin 4 Levels Are Associated with Metabolic Syndrome in Patients Newly Diagnosed with Type 2 Diabetes Mellitus. Dis Markers. 2018 Mar 12;2018:6974191. doi: 10.1155/2018/6974191. eCollection 2018.
PubMed 29721105Kurek Eken M, Sahin Ersoy G, Yayla Abide C, Sanverdi I, Devranoglu B, Kutlu T, Cevik O. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome. J Obstet Gynaecol. 2019 Oct;39(7):975-980. doi: 10.1080/01443615.2019.1581754. Epub 2019 May 7.
PubMed 31064233Villarroya F, Cereijo R, Villarroya J, Giralt M. Brown adipose tissue as a secretory organ. Nat Rev Endocrinol. 2017 Jan;13(1):26-35. doi: 10.1038/nrendo.2016.136. Epub 2016 Sep 12.
PubMed 27616452Choe SS, Huh JY, Hwang IJ, Kim JI, Kim JB. Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders. Front Endocrinol (Lausanne). 2016 Apr 13;7:30. doi: 10.3389/fendo.2016.00030. eCollection 2016.
PubMed 27148161
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Relationship Between Serum Neuregulin-4 (NRG4) Levels, Obesity Status, and Antidiabetic Treatment Regimens in Patients With Type 2 Diabetes Mellitus: A Prospective Observational Study
- ClinicalTrials.gov ID
- NCT07734558
- Acronym / sponsor ID
- NRG4-T2DM / KAEK/2026.04.1 l8
- Keywords
- Neuregulin-4, NRG4, Type 2 Diabetes Mellitus, Obesity, Adipokine
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 125 participants (estimated)
- Lead sponsor
- GÜLDEN ANATACAUniversity, hospital or other
- Study start
- Jun 2026 (estimated)
- Primary completion
- 30 Aug 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 29 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective observational study aims to evaluate serum Neuregulin-4 (NRG4) concentrations in obese and non-obese adults with Type 2 Diabetes Mellitus (T2DM) and to investigate their association with obesity status, insulin resistance, and different antidiabetic treatment regimens. Participants will be categorized into five predefined groups according to obesity status and treatment regimen, including SGLT2 inhibitor users, non-SGLT2 oral antidiabetic therapy users, SGLT2 combination therapy users, newly diagnosed treatment-naïve patients, and healthy controls. Clinical, anthropometric, and laboratory parameters including fasting plasma glucose, HbA1c, estimated glomerular filtration rate (eGFR), body mass index, waist circumference, waist-to-hip ratio, and serum NRG4 concentrations will be evaluated. The study aims to determine whether NRG4 may serve as a novel biomarker reflecting metabolic status and treatment response in patients with T2DM.
Detailed description
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, resulting in persistent hyperglycemia and an increased risk of both microvascular and macrovascular complications. Obesity is one of the strongest risk factors for the development and progression of T2DM and is associated with chronic low-grade inflammation, dysregulated adipokine secretion, and impaired glucose and lipid metabolism. Despite advances in antidiabetic therapies, identifying novel biomarkers that reflect metabolic status and treatment response remains an important research priority.
Neuregulin-4 (NRG4) is a recently identified adipokine predominantly secreted by brown adipose tissue. Experimental and clinical studies have demonstrated that NRG4 plays an important role in maintaining metabolic homeostasis by regulating glucose metabolism, improving insulin sensitivity, suppressing hepatic lipogenesis, and reducing systemic inflammation. Reduced circulating NRG4 concentrations have been associated with obesity, insulin resistance, non-alcoholic fatty liver disease, metabolic syndrome, and Type 2 Diabetes Mellitus. Lower serum NRG4 levels may therefore represent a potential biomarker of metabolic dysfunction and disease severity.
Although previous studies have investigated the association between serum NRG4 concentrations and obesity or T2DM separately, limited evidence is available regarding the relationship between NRG4 levels, obesity status, and different antidiabetic treatment regimens within the same patient population. In particular, the potential influence of sodium-glucose cotransporter-2 (SGLT2) inhibitors and other commonly used antidiabetic therapies on circulating NRG4 concentrations has not been adequately investigated.
This single-center, prospective observational study aims to evaluate serum NRG4 concentrations in obese and non-obese adults with Type 2 Diabetes Mellitus and to investigate their relationship with different antidiabetic treatment regimens. Participants will be consecutively recruited from the outpatient clinic and classified into five predefined groups according to diabetes status and current treatment regimen: (1) patients receiving SGLT2 inhibitor monotherapy; (2) patients receiving oral antidiabetic therapy without SGLT2 inhibitors; (3) patients receiving combination therapy including SGLT2 inhibitors; (4) newly diagnosed treatment-naïve patients with T2DM; and (5) healthy individuals without diabetes who will serve as the control group.
Clinical and demographic characteristics including age, sex, body mass index (BMI), waist circumference, waist-to-hip ratio, smoking status, and current antidiabetic medications will be recorded. Routine biochemical parameters, including fasting plasma glucose, glycated hemoglobin (HbA1c), and estimated glomerular filtration rate (eGFR), will be obtained from routine clinical evaluations. In addition, one peripheral venous blood sample will be collected from each participant for serum NRG4 measurement. Blood samples will be centrifuged, serum aliquots will be stored at -80°C, and serum NRG4 concentrations will be measured using a validated enzyme-linked immunosorbent assay (ELISA).
The primary outcome of the study is the comparison of serum NRG4 concentrations among the predefined study groups. Secondary analyses will evaluate the associations between serum NRG4 concentrations and obesity-related anthropometric measurements, glycemic control, renal function, and different antidiabetic treatment modalities.
The findings of this study are expected to improve the understanding of the role of NRG4 in the pathophysiology of obesity and Type 2 Diabetes Mellitus and may provide evidence supporting the clinical utility of NRG4 as a novel biomarker for metabolic status and treatment response. The results may also contribute to the identification of future therapeutic targets for patients with obesity and T2DM.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| SGLT2 Group | – | –Type 2 Diabetes Mellitus patients receiving only SGLT2 inhibitor treatment will be included in this group. Serum NRG4 levels and metabolic parameters will be evaluated. |
| Non-SGLT2 OAD Group | – | –Type 2 Diabetes Mellitus patients receiving metformin with or without insulin therapy, but not receiving SGLT2 inhibitors, will be included in this group. |
| SGLT2 Combination Group | – | –Type 2 Diabetes Mellitus patients receiving metformin with or without insulin together with SGLT2 inhibitor therapy will be included in this group. |
| Newly Diagnosed DM Group | – | –Newly diagnosed treatment-naive Type 2 Diabetes Mellitus patients who have not received any antidiabetic therapy will be included in this group. |
| Healthy Control Group | – | –Age-matched participants without Diabetes Mellitus diagnosis will be included as healthy controls for comparison of serum NRG4 levels and metabolic parameters. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of obese and non-obese adult participants aged 18-65 years who are admitted to the outpatient clinic. The study will include newly diagnosed treatment-naive Type 2 Diabetes Mellitus patients, patients with at least 6 months of Type 2 DM diagnosis receiving different antidiabetic treatment combinations, and healthy control participants without diabetes mellitus.
Key inclusion criteria (10 listed)
- Age 18-65 years
- Newly diagnosed treatment-naïve T2DM
- T2DM treated for at least 6 months
- BMI >30 kg/m²
- BMI <25 kg/m²
Key exclusion criteria (6 listed)
- Age <18 years
- Pregnancy
- Breastfeeding
- Active infection
- Rheumatologic disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Serum Neuregulin-4 (NRG4) Levels in Obese and Non-Obese Type 2 Diabetic Patients
Time frame: Baseline (Day 0)
The primary outcome of this study is the evaluation and comparison of serum Neuregulin-4 (NRG4) levels among obese and non-obese patients with Type 2 Diabetes Mellitus receiving different antidiabetic treatment modalities, as well as healthy control subjects.
4 secondary outcomes
Glycated Hemoglobin (HbA1c)
Time frame: Baseline (Day 0)
Fasting Plasma Glucose
Time frame: Baseline (Day 0)
Estimated Glomerular Filtration Rate (eGFR)
Time frame: Baseline (Day 0)
Body Mass Index (BMI)
Time frame: Baseline (Day 0)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2026.
- Background: PubMed 34159710Tutunchi H, Mobasseri M, Aghamohammadzadeh N, Hooshyar J, Naeini F, Najafipour F. Serum neuregulin 4 (NRG-4) level and non-alcoholic fatty liver disease (NAFLD): A case-control study. Int J Clin Pract. 2021 Oct;75(10):e14555. doi: 10.1111/ijcp.14555. Epub 2021 Jun 29.
- Background: PubMed 27772531Cai C, Lin M, Xu Y, Li X, Yang S, Zhang H. Association of circulating neuregulin 4 with metabolic syndrome in obese adults: a cross-sectional study. BMC Med. 2016 Oct 24;14(1):165. doi: 10.1186/s12916-016-0703-6.
- Background: PubMed 25401691Wang GX, Zhao XY, Meng ZX, Kern M, Dietrich A, Chen Z, Cozacov Z, Zhou D, Okunade AL, Su X, Li S, Bluher M, Lin JD. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. Nat Med. 2014 Dec;20(12):1436-1443. doi: 10.1038/nm.3713. Epub 2014 Nov 17.
- Background: PubMed 29721105Yan P, Xu Y, Wan Q, Feng J, Li H, Yang J, Zhong H, Zhang Z. Plasma Neuregulin 4 Levels Are Associated with Metabolic Syndrome in Patients Newly Diagnosed with Type 2 Diabetes Mellitus. Dis Markers. 2018 Mar 12;2018:6974191. doi: 10.1155/2018/6974191. eCollection 2018.
- Background: PubMed 31064233Kurek Eken M, Sahin Ersoy G, Yayla Abide C, Sanverdi I, Devranoglu B, Kutlu T, Cevik O. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome. J Obstet Gynaecol. 2019 Oct;39(7):975-980. doi: 10.1080/01443615.2019.1581754. Epub 2019 May 7.
- Background: PubMed 27616452Villarroya F, Cereijo R, Villarroya J, Giralt M. Brown adipose tissue as a secretory organ. Nat Rev Endocrinol. 2017 Jan;13(1):26-35. doi: 10.1038/nrendo.2016.136. Epub 2016 Sep 12.
- Background: PubMed 27148161Choe SS, Huh JY, Hwang IJ, Kim JI, Kim JB. Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders. Front Endocrinol (Lausanne). 2016 Apr 13;7:30. doi: 10.3389/fendo.2016.00030. eCollection 2016.
- Individual participant dataSharing planned: No. ndividual participant data (IPD) will not be shared in order to protect participant confidentiality and privacy. The study will report only aggregated and anonymized data in scientific publications and presentations.
Related trials for Type 2 Diabetes Mellitus (T2DM)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 2
A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
RecruitingPhase 3
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Obesity, Overweight
RecruitingObservational study
Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes
T2DM (Type 2 Diabetes Mellitus)
Active, not recruitingObservational study
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Type 2 Diabetes Mellitus (T2DM) and Obesity Type 2 Diabetes Mellitus, run by GÜLDEN ANATACA at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact GÜLDEN ANATACA (+905059284244, ganataca@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum Neuregulin-4 (NRG4) Levels in Obese and Non-Obese Type 2 Diabetic Patients (time frame: Baseline (Day 0)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07734558, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2026.